London · Delayed Price · Currency is GBP · Price in USD AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of GBP 220.48 billion. The enterprise value is 238.75 billion.
| Market Cap | 220.48B |
| Enterprise Value | 238.75B |
Important Dates
The next estimated earnings date is Tuesday, February 10, 2026.
| Earnings Date | Feb 10, 2026 |
| Ex-Dividend Date | Aug 8, 2025 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.08% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | 0.03% |
| Owned by Institutions (%) | 80.78% |
| Float | 1.54B |
Valuation Ratios
The trailing PE ratio is 31.53 and the forward PE ratio is 18.92.
| PE Ratio | 31.53 |
| Forward PE | 18.92 |
| PS Ratio | 5.10 |
| PB Ratio | 6.45 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 23.41 |
| P/OCF Ratio | 19.57 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.47, with an EV/FCF ratio of 25.35.
| EV / Earnings | 34.14 |
| EV / Sales | 5.52 |
| EV / EBITDA | 15.47 |
| EV / EBIT | 20.19 |
| EV / FCF | 25.35 |
Financial Position
The company has a current ratio of 0.88, with a Debt / Equity ratio of 0.71.
| Current Ratio | 0.88 |
| Quick Ratio | 0.69 |
| Debt / Equity | 0.71 |
| Debt / EBITDA | 1.57 |
| Debt / FCF | 2.58 |
| Interest Coverage | 12.24 |
Financial Efficiency
Return on equity (ROE) is 21.67% and return on invested capital (ROIC) is 13.16%.
| Return on Equity (ROE) | 21.67% |
| Return on Assets (ROA) | 9.06% |
| Return on Invested Capital (ROIC) | 13.16% |
| Return on Capital Employed (ROCE) | 19.78% |
| Revenue Per Employee | 458,568 |
| Profits Per Employee | 74,149 |
| Employee Count | 94,300 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 1.59 |
Taxes
In the past 12 months, AstraZeneca has paid 1.51 billion in taxes.
| Income Tax | 1.51B |
| Effective Tax Rate | 17.79% |
Stock Price Statistics
The stock price has increased by +42.00% in the last 52 weeks. The beta is 0.18, so AstraZeneca's price volatility has been lower than the market average.
| Beta (5Y) | 0.18 |
| 52-Week Price Change | +42.00% |
| 50-Day Moving Average | 70.48 |
| 200-Day Moving Average | 75.43 |
| Relative Strength Index (RSI) | 72.78 |
| Average Volume (20 Days) | 6,964 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AstraZeneca had revenue of GBP 43.24 billion and earned 6.99 billion in profits. Earnings per share was 4.48.
| Revenue | 43.24B |
| Gross Profit | 36.00B |
| Operating Income | 11.83B |
| Pretax Income | 8.51B |
| Net Income | 6.99B |
| EBITDA | 15.19B |
| EBIT | 11.83B |
| Earnings Per Share (EPS) | 4.48 |
Balance Sheet
The company has 6.09 billion in cash and 24.30 billion in debt, with a net cash position of -18.21 billion.
| Cash & Cash Equivalents | 6.09B |
| Total Debt | 24.30B |
| Net Cash | -18.21B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 34.20B |
| Book Value Per Share | 22.01 |
| Working Capital | -3.06B |
Cash Flow
In the last 12 months, operating cash flow was 11.26 billion and capital expenditures -1.85 billion, giving a free cash flow of 9.42 billion.
| Operating Cash Flow | 11.26B |
| Capital Expenditures | -1.85B |
| Free Cash Flow | 9.42B |
| FCF Per Share | n/a |
Margins
Gross margin is 83.26%, with operating and profit margins of 27.37% and 16.17%.
| Gross Margin | 83.26% |
| Operating Margin | 27.37% |
| Pretax Margin | 19.68% |
| Profit Margin | 16.17% |
| EBITDA Margin | 35.12% |
| EBIT Margin | 27.37% |
| FCF Margin | 21.78% |
Dividends & Yields
This stock pays an annual dividend of 1.14, which amounts to a dividend yield of 1.20%.
| Dividend Per Share | 1.14 |
| Dividend Yield | 1.20% |
| Dividend Growth (YoY) | 5.50% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 52.89% |
| Buyback Yield | 0.08% |
| Shareholder Yield | 1.28% |
| Earnings Yield | 3.17% |
| FCF Yield | 4.27% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 8, 1998. It was a forward split with a ratio of 3.
| Last Split Date | Apr 8, 1998 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
AstraZeneca has an Altman Z-Score of 2.98 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.98 |
| Piotroski F-Score | 7 |